Clifford Swan Investment Counsel’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$18.3M Sell
301,465
-8,028
-3% -$468K 0.62% 49
2025
Q4
$16.7M Sell
309,493
-16,535
-5% -$795K 0.55% 50
2025
Q3
$14.7M Sell
326,028
-21,972
-6% -$1.03M 0.49% 62
2025
Q2
$16.1M Sell
348,000
-52,795
-13% -$2.59M 0.57% 51
2025
Q1
$24.4M Sell
400,795
-26,243
-6% -$1.53M 0.9% 35
2024
Q4
$24.2M Sell
427,038
-30,078
-7% -$1.68M 0.87% 34
2024
Q3
$23.7M Buy
457,116
+51,537
+13% +$2.42M 0.84% 36
2024
Q2
$16.8M Sell
405,579
-15,549
-4% -$696K 0.63% 51
2024
Q1
$22.8M Sell
421,128
-2,696
-0.6% -$137K 0.85% 37
2023
Q4
$21.7M Sell
423,824
-14,923
-3% -$783K 0.85% 36
2023
Q3
$25.5M Sell
438,747
-2,251
-0.5% -$138K 1.07% 21
2023
Q2
$28.2M Sell
440,998
-3,869
-0.9% -$259K 1.14% 18
2023
Q1
$30.8M Sell
444,867
-2,615
-0.6% -$184K 1.29% 14
2022
Q4
$32.2M Sell
447,482
-22,166
-5% -$1.67M 1.4% 13
2022
Q3
$33.4M Sell
469,648
-25,275
-5% -$1.83M 1.57% 11
2022
Q2
$38.1M Sell
494,923
-10,324
-2% -$786K 1.65% 11
2022
Q1
$36.9M Sell
505,247
-20,242
-4% -$1.36M 1.37% 12
2021
Q4
$32.8M Buy
525,489
+376
+0.1% +$22.1K 1.15% 22
2021
Q3
$30.8M Buy
525,113
+4,030
+0.8% +$265K 1.13% 24
2021
Q2
$35.7M Buy
521,083
+12
+0% +$782 1.35% 15
2021
Q1
$32.9M Buy
521,071
+854
+0.2% +$53.1K 1.35% 18
2020
Q4
$32.3M Sell
520,217
-14,043
-3% -$864K 1.41% 15
2020
Q3
$32.2M Sell
534,260
-118
-0% -$7.1K 1.54% 13
2020
Q2
$31.4M Sell
534,378
-4,747
-0.9% -$284K 1.62% 12
2020
Q1
$30.1M Sell
539,125
-1,655
-0.3% -$101K 1.83% 9
2019
Q4
$34.7M Buy
540,780
+3,060
+0.6% +$175K 1.68% 10
2019
Q3
$27.3M Buy
537,720
+13,474
+3% +$633K 1.42% 17
2019
Q2
$23.8M Buy
524,246
+39,198
+8% +$1.83M 1.25% 24
2019
Q1
$23.1M Buy
485,048
+28,855
+6% +$1.44M 1.24% 24
2018
Q4
$23.7M Buy
456,193
+484
+0.1% +$26K 1.44% 18
2018
Q3
$28.3M Buy
455,709
+9,232
+2% +$548K 1.47% 14
2018
Q2
$24.7M Buy
446,477
+7,133
+2% +$385K 1.38% 15
2018
Q1
$27.8M Sell
439,344
-6,216
-1% -$400K 1.57% 13
2017
Q4
$27.3M Buy
445,560
+94,541
+27% +$5.91M 1.49% 12
2017
Q3
$22.4M Buy
351,019
+14,345
+4% +$838K 1.35% 16
2017
Q2
$18.8M Buy
336,674
+21,777
+7% +$1.19M 1.17% 23
2017
Q1
$17.1M Buy
314,897
+91,490
+41% +$5.02M 1.1% 28
2016
Q4
$13.1M Buy
223,407
+93,310
+72% +$5.1M 0.87% 35
2016
Q3
$7.01M Buy
130,097
+32,613
+33% +$2.09M 0.47% 67
2016
Q2
$7.17M Sell
97,484
-17,077
-15% -$1.21M 0.5% 67
2016
Q1
$7.32M Sell
114,561
-13,947
-11% -$880K 0.5% 67
2015
Q4
$8.84M Sell
128,508
-1,130
-0.9% -$74.7K 0.61% 60
2015
Q3
$7.67M Sell
129,638
-3,174
-2% -$201K 0.55% 61
2015
Q2
$8.84M Sell
132,812
-3,957
-3% -$261K 0.59% 57
2015
Q1
$8.82M Sell
136,769
-364
-0.3% -$22.8K 0.58% 56
2014
Q4
$8.1M Sell
137,133
-981
-0.7% -$55.3K 0.53% 55
2014
Q3
$7.07M Buy
138,114
+185
+0.1% +$9.24K 0.48% 63
2014
Q2
$6.69M Sell
137,929
-5,349
-4% -$264K 0.45% 63
2014
Q1
$7.44M Buy
143,278
+7,071
+5% +$376K 0.52% 56
2013
Q4
$7.24M Sell
136,207
-3,590
-3% -$183K 0.52% 56
2013
Q3
$6.47M Sell
139,797
-2,550
-2% -$112K 0.52% 57
2013
Q2
$6.36M Buy
+142,347
New +$6.18M 0.53% 56

Other funds holding BMY

Clifford Swan Investment Counsel's BMY Position: Q1 2026 in Review

Clifford Swan Investment Counsel reduced its Bristol-Myers Squibb (BMY) stake by 2.6% in Q1 2026, selling an estimated $468K and leaving 301,465 shares worth $18.3M. The position accounts for 0.62% of the portfolio, ranked #49.

Clifford Swan Investment Counsel first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $38.1M in Q2 2022. 2,527 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Clifford Swan Investment Counsel held 301,465 shares of Bristol-Myers Squibb worth $18.3M as of Q1 2026.
  • Clifford Swan Investment Counsel sold 8,028 Bristol-Myers Squibb shares in Q1 2026, an estimated $468K.
  • Bristol-Myers Squibb made up 0.62% of Clifford Swan Investment Counsel's portfolio in Q1 2026, its #49 holding.
  • Clifford Swan Investment Counsel first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Clifford Swan Investment Counsel's Bristol-Myers Squibb position peaked at $38.1M in Q2 2022.
  • 2,527 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Clifford Swan Investment Counsel's 13F filing for Q1 2026, filed 6 May 2026.